All In Biotech

Drug Trial Radar · NCT07946848

Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.

A Phase 2, Open-Label, Multicenter, Dose Optimization and Anti-Tumor Activity Study of Atebimetinib, a Novel Oral Dual MEK1/2 Inhibitor in Combinations With Cemiplimab and Chemotherapy in First Line, RAS-mutated, Locally Advanced or Metastatic NSCLC Participants

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

May 2029

Study completion Jul 2029

Sponsor

Lead sponsor
Immuneering CorporationIndustry
Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Atebimetinib Plus Cemiplimab, With or Without Chemotherapy, in First-Line RAS-Mutated Non-Small Cell Lung Cancer

Conditions

  • NSCLC (Advanced Non-small Cell Lung Cancer)
  • Non-Squamous Non Small Cell Lung Cancer
  • Metastatic Non-Small Lung Cell Cancer
  • Locally Advanced Non-Small Cell Lung Cancer
  • Lung Cancer (NSCLC)

Interventions

  • AtebimetinibDrug

    Oral dual MEK1/2 inhibitor, immediate-release tablets, given once daily continuously at 160, 240 or 320 mg

  • CemiplimabBiological

    Anti-PD-1 monoclonal antibody, 350 mg IV every 3 weeks

  • CarboplatinDrug

    AUC 5 or 6 mg/mL/min IV (Calvert formula) on Day 1 of Cycles 1-4

  • Pemetrexed (500 mg/m²)Drug

    500 mg/m² IV on Day 1 of Cycles 1-4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax), Time to Maximum Plasma Concentration (Tmax) and Area under the curve (AUC0-t) of AtebimetinibTime frame: Cycle 1 Day 1 Cycle 2 Day 1 Each cycle is 21 days.
  2. Objective Response Rate (ORR)Time frame: Every 8 weeks, up to approximately 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.